Review



a549 dualtm ko rig  (InvivoGen)


Bioz Verified Symbol InvivoGen is a verified supplier
Bioz Manufacturer Symbol InvivoGen manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    InvivoGen a549 dualtm ko rig
    A549 Dualtm Ko Rig, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 239 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/a549 dualtm ko rig/product/InvivoGen
    Average 96 stars, based on 239 article reviews
    a549 dualtm ko rig - by Bioz Stars, 2026-03
    96/100 stars

    Images



    Similar Products

    96
    InvivoGen a549 dualtm ko rig
    A549 Dualtm Ko Rig, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/a549 dualtm ko rig/product/InvivoGen
    Average 96 stars, based on 1 article reviews
    a549 dualtm ko rig - by Bioz Stars, 2026-03
    96/100 stars
      Buy from Supplier

    96
    InvivoGen a549 dual ko rig
    A549 Dual Ko Rig, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/a549 dual ko rig/product/InvivoGen
    Average 96 stars, based on 1 article reviews
    a549 dual ko rig - by Bioz Stars, 2026-03
    96/100 stars
      Buy from Supplier

    93
    InvivoGen a549 dual rig i ko
    Simultaneous activation of RIG-I and silencing of PLK1 mediated by mAb-siPLK1-5′ppp 1 on <t>A549-Dual</t> siPLK1-5′ppp was delivered by either RNAiMAX or EphA2-antibody. (A) RIG-I-dependent activation of the IRF pathway (N = 6, triplicates). (B) RIG-I-dependent activation of the NF-κB pathway (N = 6, triplicates). Dual activity of the siPLK1-5′ppp delivered by either RNAiMAX or EphA2-antibody regarding RIG-I/PLK1 expression levels or cell-cycle arrest. (C) Western-blot on RIG-I, PLK1, and GAPDH, showing a simultaneous PLK1 knockdown and RIG-I activation, 72 h after incubation at 40 nM. (D) Proportion of cells in G2/M phase analyzed by FACS after 24 h of incubation at 40 nM (N = 2, triplicates). Data are presented as mean ± SD. Significancy was assessed by comparing treated cells with non-treated cells, ns = non-significant, ∗∗∗ = p < 0.0005, ∗∗∗∗ = p < 0.00005).
    A549 Dual Rig I Ko, supplied by InvivoGen, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/a549 dual rig i ko/product/InvivoGen
    Average 93 stars, based on 1 article reviews
    a549 dual rig i ko - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    Image Search Results


    Simultaneous activation of RIG-I and silencing of PLK1 mediated by mAb-siPLK1-5′ppp 1 on A549-Dual siPLK1-5′ppp was delivered by either RNAiMAX or EphA2-antibody. (A) RIG-I-dependent activation of the IRF pathway (N = 6, triplicates). (B) RIG-I-dependent activation of the NF-κB pathway (N = 6, triplicates). Dual activity of the siPLK1-5′ppp delivered by either RNAiMAX or EphA2-antibody regarding RIG-I/PLK1 expression levels or cell-cycle arrest. (C) Western-blot on RIG-I, PLK1, and GAPDH, showing a simultaneous PLK1 knockdown and RIG-I activation, 72 h after incubation at 40 nM. (D) Proportion of cells in G2/M phase analyzed by FACS after 24 h of incubation at 40 nM (N = 2, triplicates). Data are presented as mean ± SD. Significancy was assessed by comparing treated cells with non-treated cells, ns = non-significant, ∗∗∗ = p < 0.0005, ∗∗∗∗ = p < 0.00005).

    Journal: iScience

    Article Title: Targeted delivery of immune-stimulating bispecific RNA, inducing apoptosis and anti-tumor immunity in cancer cells

    doi: 10.1016/j.isci.2024.109068

    Figure Lengend Snippet: Simultaneous activation of RIG-I and silencing of PLK1 mediated by mAb-siPLK1-5′ppp 1 on A549-Dual siPLK1-5′ppp was delivered by either RNAiMAX or EphA2-antibody. (A) RIG-I-dependent activation of the IRF pathway (N = 6, triplicates). (B) RIG-I-dependent activation of the NF-κB pathway (N = 6, triplicates). Dual activity of the siPLK1-5′ppp delivered by either RNAiMAX or EphA2-antibody regarding RIG-I/PLK1 expression levels or cell-cycle arrest. (C) Western-blot on RIG-I, PLK1, and GAPDH, showing a simultaneous PLK1 knockdown and RIG-I activation, 72 h after incubation at 40 nM. (D) Proportion of cells in G2/M phase analyzed by FACS after 24 h of incubation at 40 nM (N = 2, triplicates). Data are presented as mean ± SD. Significancy was assessed by comparing treated cells with non-treated cells, ns = non-significant, ∗∗∗ = p < 0.0005, ∗∗∗∗ = p < 0.00005).

    Article Snippet: A549-Dual RIG-I KO , InvivoGen , a549d-korigi.

    Techniques: Activation Assay, Activity Assay, Expressing, Western Blot, Knockdown, Incubation

    mAb-siPLK1-5′ppp induces A549-Dual cell death by apoptosis and activates PBMCs to promote anti-tumor inflammation A549-Dual confluence over time after treatments with transfected siRNAs (A) or ARCs (B for A549 cells alone, C for a mixture of A549/PBMC: 1/5). One picture of A549 cells was taken every 2 h for 4 days, PBMC were excluded by the software because of the difference of size between A549 and PBMC, N = 2 with two different donors of PBMCs—(D) Cytokine quantification after mAb-siRNA-5′ppp 1 treatment for 24 h at 100 nM to the A549/PBMC mixture. Data are presented as mean ± SD. Significancy was assessed by comparing the secreted cytokine obtained from mAb-siRNA-5′ppp 1 compared to the non-treated mixture of cells (ns = non-significant, ∗ = p < 0.05, ∗∗ = p < 0.005, ∗∗∗ = p < 0.0005, ∗∗∗∗ = p < 0.00005), N = 1, triplicates.

    Journal: iScience

    Article Title: Targeted delivery of immune-stimulating bispecific RNA, inducing apoptosis and anti-tumor immunity in cancer cells

    doi: 10.1016/j.isci.2024.109068

    Figure Lengend Snippet: mAb-siPLK1-5′ppp induces A549-Dual cell death by apoptosis and activates PBMCs to promote anti-tumor inflammation A549-Dual confluence over time after treatments with transfected siRNAs (A) or ARCs (B for A549 cells alone, C for a mixture of A549/PBMC: 1/5). One picture of A549 cells was taken every 2 h for 4 days, PBMC were excluded by the software because of the difference of size between A549 and PBMC, N = 2 with two different donors of PBMCs—(D) Cytokine quantification after mAb-siRNA-5′ppp 1 treatment for 24 h at 100 nM to the A549/PBMC mixture. Data are presented as mean ± SD. Significancy was assessed by comparing the secreted cytokine obtained from mAb-siRNA-5′ppp 1 compared to the non-treated mixture of cells (ns = non-significant, ∗ = p < 0.05, ∗∗ = p < 0.005, ∗∗∗ = p < 0.0005, ∗∗∗∗ = p < 0.00005), N = 1, triplicates.

    Article Snippet: A549-Dual RIG-I KO , InvivoGen , a549d-korigi.

    Techniques: Transfection, Software

    Journal: iScience

    Article Title: Targeted delivery of immune-stimulating bispecific RNA, inducing apoptosis and anti-tumor immunity in cancer cells

    doi: 10.1016/j.isci.2024.109068

    Figure Lengend Snippet:

    Article Snippet: A549-Dual RIG-I KO , InvivoGen , a549d-korigi.

    Techniques: Isolation, Recombinant, WST-1 Assay, Control, Software